Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Self-Sealing Needle Prevents Blood Loss in Those with Bleeding Disorders

XTALKS VITALS NEWS

Injection

For those with bleeding disorders – including hemophilia – an injection using a standard needle could result in an uncontrolled loss of blood.

Share this!

October 28, 2016 | by Sarah Hand, M.Sc.

Most patients experience a minimal amount of bleeding after receiving an injection. But for those with bleeding disorders – including hemophilia – an injection using a standard needle could result in an uncontrolled loss of blood.

Researchers in Korea have developed a novel biodegradable polymer, which can be used to coat the needle and effectively seal an injection site. The research was published in the journal, Nature Materials.

“Bleeding is largely unavoidable following syringe needle puncture of biological tissues and, while inconvenient, this typically causes little or no harm in healthy individuals,” said the researchers in their publication. “However, there are certain circumstances where syringe injections can have more significant side effects, such as uncontrolled bleeding in those with hemophilia, coagulopathy, or the transmission of infectious diseases through contaminated blood.”



According to the Centers for Disease Control and Prevention (CDC), it’s estimated that 20,000 people in the US are living with hemophilia. The bleeding disorder results from a deficiency, or total lack of, the clotting factors necessary to prevent uncontrolled bleeding.

The majority of people with hemophilia are diagnosed at a very young age, with some of the most severe forms being identified in patients as young as one month. Approximately two thirds of cases of the bleeding disorder – for which there is no known cure – occur in people with a family history of the disease.

The polymer developed by the Korean researchers is derived from chitosan, a component of crustacean shells. The gel polymer hardens upon contact with blood to prevent post-injection bleeding.

The researchers compared the polymer-coated needles to regular needles in mouse models of hemophilia. All of the mice injected with standard needles died as a result of uncontrolled bleeding. Those who were injected with the polymer-coated needles however, saw a 100 percent survival rate.

So far, the coated needles have only been tested in preclinical studies, but the promising results have the potential to apply to human patients as well. “Such self-sealing haemostatic needles and adhesive coatings may therefore help to prevent complications associated with bleeding in more clinical settings,” said the researchers.


Keywords: Hemophilia, Injection, Animal Model


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.